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Abstract 
The prescription of opioid analgesics has risen sharply in North America over the past 
two decades. This increase has been accompanied by a rise in overdoses. The 
present study draws on administrative data collected from emergency department 
contacts to describe the epidemiology of opioid overdose in Ontario b~tween 2002 
and 2006 and to examine the role of regional variation in availability of specialist 
care. 
The number of poisonings increased from 1250 (10.9 per 100,000) in FY2002 to 
1816 (15.2 per 100,000) in FY2005. Local concentration of specialist physicians was 
significantly associated with the incidence of opioid overdose, inversely at most 
levels of availability, but positively at very high levels. Regional variation in 
incidence was also associated with demographics, median family income, and the rate 
of other drug poisonings. Policy options for limiting opioid-related harms are limited, 
but improvements in monitoring and clinical management may prove valuable. 
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Opioids: Description and pharmacology 
The opioids comprise a broad class of drugs with effects similar to those of opium 
and other derivatives of the opium poppy. They include opiates, which are natural 
alkaloids derived from the plant itself (e. g., codeine, morphine), semi -synthetic drugs 
produced from these substances (e.g., heroin, oxycodone), and fully synthetic drugs 
(e.g., methadone, tramadol) (Kalant, 2006). Opioids medications currently widely 
prescribed in Canada are listed in table 1. 
All widely-used opioids are more or less potent analgesics and have a variety of other 
effects, including sedation, improved mood, and suppression of the cough reflex 
(Merck 2008; Kalant, 2006; Benyamin et al. 2008). Common undesirable side effects 
of opioids include constipation, dizziness, nausea, vomiting, paradoxical 
hypersensitivity to pain, hormonal changes, and respiratory depression. The majority 
are also capable of producing euphoria, which has led to widespread non-medical use. 
Opioids are effective because of their similarity to chemicals produced by the body 
that modulate a number of behavioral drives and biological functions (Akil et al. 
1998; Van Ree et al. 2000). These 'endogenous opioids,' including endorphins, 
enkephalins, dynorphins, and endomorphins, play important roles in respiration, 
digestive system function, sexual drive, social behaviour, analgesia, and reward. 
Medically, opioids are most commonly used for analgesia in cases of moderate or 
severe pain. They may be prescribed for postsurgical pain or traumatic injury, or to 
manage chronic conditions such as cancer, lower back pain, neuropathic pain, or 
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osteoarthritis. Other medical uses, which typically involve low doses or relatively 
low-potency opioids such as codeine, include the treatment of diarrhea or coughing. 
While alternatives exist for their other uses, opioids are indispensable for the 
treatment of pain, for which there are no other drug or non-drug therapies of 
comparable effectiveness (WHO, 2000). A less widely-appreciated effect of opioids 
is the reduction of suffering generally, including emotional distress. Physical and 
emotional pain share common neurochemical bases (e.g., Vastag, 2003), and, in the 
same way that antidepressants have proven effective against some forms of chronic 
pain (e.g., Ansari 2000), opioids appear to be effective against depression and 
anxiety (Jamison et al. 1998; Haythornthwaite et al. 1998). This may be an important 
component of opioid therapy in palliative care, and may also account for some of 
their wider use, both medical (Sullivan et al. 2005) and non-medical. 
Table 1. Widely-prescribed opioids. 
Opioid 
Morphine 
Codeine 
Oxycodone 
Hydrocodone 
Hydromorphone 
Methadone 
Meperidine 
Fentanyl* 
Trade names 
MS Contin, Oramorph 
Tylenol 2, 3, 4 
OxyContin, Percocet, Percodan, Tylox 
Vicodin 
Palladone, Dilaudid, Hydromorph Contin 
Dolophine 
Demerol 
Duragesic, Actiq 
* Limited consensus on equianalgesic dose. 
* * For trans dermal dose. 
*** Includes combination preparations. 
Approximate 
relative 
potency for 
analgesia (oral 
dose; 
morphine = 1) 
1 
0.1 
2 
0.5 
4 
1.5 
0.125 
150** 
Sources: Galvagno et al. (2007); Nissen et al. (2001), IMS Health. 
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Doses (all 
strengths) 
dispensed at 
Ontario retail 
pharmacies, 
2005 
(millions)*** 
32.2 
242.4 
43.6 
27.0 
23.6 
1.0 
4.6 
2.9 
I; 
The other significant medical use of opioids is in agonist therapy for opioid 
dependence. Since opioids are cross-tolerant (Kalant, 2006), giving one drug can 
reduce or eliminate symptoms of withdrawal from another. The prototypical form of 
" 
opioid agonist therapy is maintenance therapy for heroin dependence, in which people 
" 
dependent on heroin are given regular doses of another opioid, usually methadone or 
buprenorphine (First & Tasman, 2006). This ameliorates withdrawal symptoms and 
reduces cravings for the preferred drug. Methadone and buprenorphine also reduce or 
eliminate the euphoria and other positive effects felt ifuse of heroin or another opioid 
is resumed, and buprenorphine is sometimes given in a formulation that includes the 
opioid antagonist naloxone, with the intention of preventing intravenous and other 
unintended use. 
Opioid safety 
Opioids do not cause direct organ damage even with heavy, long-term use, and are 
generally regarded as remarkably non-toxic (Kalant, 2006). In medical contexts, 
most practical issues with opioids, apart from misuse and physical dependence, arise 
from relatively benign side effects. There is, however, some evidence linking opioids 
to various health problems. Chronic use appears to interfere with immune function, 
and it has been suggested that this may contribute to the very high prevalence of 
infectious disease among heroin users (Vallejo et aI., 2004). Methadone and the long-
acting opioid levo-alpha acetyl methadol (LAAM) - used extensively, until recently, 
in agonist therapy for opioid dependence (Jaffe, 2007) - have also been shown to 
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increase risk for heart rhythm abnormalities, including Q-T prolongation and torsades 
des pointes (Krantz et al., 2003; Krantz et aI., 2002). Finally, meperidine (Demerol) 
has been linked to certain neuropsychiatric side effects, which have led in recent 
years to substantial reductions in its use (Latta et aI., 2002). 
A more common concern with opioid use is the potential of all important drugs in this 
class for misuse. Opioids are both habit-forming and physiologically addictive. 
Regular use quickly results in tolerance and habituation, and a withdrawal syndrome 
will occur if use is stopped suddenly or an antagonist drug is used. While not usually 
medically dangerous, opioid withdrawal is notoriously unpleasant, with symptoms 
including hypersensitivity to pain, dysphoria, aches, restlessness, sweating, chills, 
piloerection, irritability, anxiety, weakness, cramps, insomnia, nausea, diarrhea, and 
hypertension. Induction of sudden, severe opioid withdrawal has been described by 
those who have experienced it as "the worst feeling in the world" (Worthington et aI., 
2006). 
Cessation of use in non-medical users is also likely to result in strong drug cravings 
(Kalant, 2006; First & Tasman 2006). Although opioids such as diacetylmorphine 
(heroin) and morphine have historically been thought to be uniquely appealing to 
recreational users, most strong opioids appear to be roughly comparable in terms of 
their potential for misuse. A recent experiment in which several different opioids 
were administered to morphine-maintained heroin-dependent individuals reported 
that oxycodone was, in fact, preferred even to heroin (Comer et al. 2008). 
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Opioid overdose 
Misuse of opioids is an important factor in their other significant drawback, the risk 
of overdose. If taken in large quantities, most useful opioids cause suppression of the 
• 
respiratory centres of the brainstem (White & Irvine, 1999); breathing slows and may 
:. 
eventually cease, leading to death from hypoxia. Associated signs and conditions 
include pulmonary or cerebral edema, miosis, cyanosis, and coma (Merck manual; 
Kalant, 2006; White & Irvine 1999). Opioids' emetic and antitussive effects can 
present a further danger from aspiration of vomit (Henry, 1994). 
Death from opioid poisoning is usually slow. Several studies (reviewed in Warner-
Smith, 2001) have shown that a large proportion of fatal heroin overdoses occur over 
a period of hours. In the case of methadone, which has an exceptionally long half-life 
and accumulates over time, signs of overdose may be apparent days, and are usually 
visible for hours, before death (Caplehom 1998). Treatment for overdose is very 
effective if medical attention is sought promptly; the opioid antagonist naloxone can 
rapidly reverse an overdose, albeit sometimes at the cost of precipitating instant 
withdrawal. If necessary, mechanical ventilation can be also used to maintain 
oxygenation (Greene et aI., 2005). 
Opioid overdose typically occurs when one or more of four risk factors are present: 
resumption of use after a period of abstinence or detoxification; use of a substance of 
unknown purity; use by an individual with health problems that impair hepatic or 
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pulmonary function; or use in combination with other drugs. The first two of these 
occur principally among illicit users. The purity of heroin is difficult for users to 
establish, and may vary considerably over time or between areas. Increases in the 
purity of available heroin has been shown to be associated with increases in overdose 
" deaths (Darke, 1999). In the context of misuse of prescription opioids" a possibly 
analogous problem is confusion over or misrepresentation of the active drug or dose 
thereof. 
An issue more germane to the present study is that users, both licit and illicit, often 
fail to appreciate the dangers posed by changes in tolerance (Gitlow 2002), which is 
quickly eroded by abstinence. If a former user takes his or her typical dose after a 
period of non-use, the risk of overdose becomes extreme. The incidence of fatal 
overdose among heroin users recently released from prison - where limited access to 
narcotics usually means a period of enforced abstinence - is particularly high 
(Seamean 1998). This problem has also been frequently noted, however, in the 
context of drug treatment, particularly following courses of treatment with the opioid 
antagonist naltrexone (Gibson & Degenhardt, 2007). Although the vast majority of 
the extant literature deals with heroin overdose, these two factors may also playa role 
among users of prescription drugs. Patients or users who stop and then resume use of 
opioid medications may experience overdose as the result of lost tolerance, and this 
outcome may also occur as the result of confusion over dosages or drug names 
(particularly when these drugs are used non-medically). 
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The other significant risk factor, combination of opioids with other drugs, is the norm 
rather than the exception in fatal opioid overdoses among both medical and illicit 
users. A number of studies have reported that other substances are found at autopsy 
in the majority of deaths attributed to heroin overdose (Darke & Zador, 1994; Coffin 
et aI., 2003), while a recent American study found that other potential!y contributing 
substances were present in 97% of deaths involving oxycodone between 1999 and 
2002 (Cone et aI., 2003). A review ofhydromorphone fatalities in Ontario similarly 
found that alcohol or other drugs were present in the majority of cases (Wallage & 
Palmentier 2006). 
The substances that most commonly playa role in deaths from opioid poisoning are 
other widely-used respiratory depressants. Benzodiazepines such as diazepam 
(Valium), lorazepam (Ativan), and alprazolam (Xanax) are particularly prominent in 
fatal overdoses (White & Irvine 1998). Although other medications such as 
barbiturates have similar or greater potential to cause respiratory depression, they are 
now much less widely prescribed than the benzodiazepines (Lader, 1991). Since 
alcohol is by far the most widely-used intoxicating drug in North America and has 
independent respiratory depressant effects, it too often plays a role in opioid 
overdose. The release of some sustained-release prescription opioids may also be 
accelerated by alcohol. This has been shown to be the case for hydromorphone 
preparations, which has led Health Canada to recommend that patients be cautioned 
against this combination (Murray & Wooltorton 2005). 
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Roles for alcohol and benzodiazepines are supported by forensic and other evidence. 
Blood alcohol levels and blood opioid levels have been shown to be negatively 
correlated among victims of fatal overdose, which indicates that alcohol appears to 
lower the lethality threshold for opioid poisoning (Zador et aI., 1996). Similarly, a 
recent review of fatal heroin overdoses in the United Kingdom found ,0-at evidence of 
recent benzodiazepine use was significantly more common in these cases, at 48%, 
than among people presenting for treatment of heroin dependence (26%) (Oliver et 
aI., 2007). Use ofbenzodiazepines and related drugs is also common among people 
with physical health problems (Neutel, 2005), and issues surrounding their 
prescription are similar to those associated with the use of opioids. 
There is also some evidence that pre-existing health problems can heighten the risk of 
opioid overdose. It has been suggested that poor liver functioning, in particular, is a 
common and important risk factor (Warner-Smith 2001; Darke 2006). Since opioids 
are metabolized in the liver, reduced clearance in people with impaired hepatic 
function may result in a lengthened period of respiratory depression. It has been 
argued that hepatitis C, which is highly prevalent among injection drug users, may 
playa role in some heroin poisonings through its effects on liver functioning 
(Warner-Smith 2001). A further possibility relevant to prescription opioids concerns 
acetaminophen, which is hepatotoxic in large doses (Routledge et aI., 1998) and 
which is combined with opioid analgesics in many preparations. Use of large 
quantities of acetaminophen-containing medications (e.g., Tylenol 1, Tylenol 3, 
Percocet) may result in impaired liver function, which could increase susceptibility to 
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opioid poisoning. Alternatively, overdose on a medication containing acetaminophen 
may lead to simultaneous opioid and acetaminophen poisoning, or to primary 
acetaminophen poisoning complicated by opioid intoxication. Reduced pulmonary 
function as the result of smoking, either of tobacco or of other drugs, may also 
• 
exacerbate the effects of slowed respiration after a large dose of opioids (Warner-
;. 
Smith 2001). Since liver and lung functioning may also be more commonly impaired 
among both legitimate medical users and illicit users of opioids, these considerations 
may also be relevant to overdose from prescription drugs. 
Although other factors are usual in poisonings, opioids may also be dangerous or fatal 
on their own if taken in excessive amounts. In the context of medical use, opioid-
only overdoses have occurred as the result of misunderstandings about appropriate 
use, consumption of more than the prescribed dose, or other unfortunate 
circumstances. Overdoses of the highly potent opioid fentanyl, for example, have 
occurred from the use of heating blankets with transdermal patches, which accelerates 
the release of medication (Frolich et al. 1998; Carter 2003). 
Epidemiology of opioid use 
The vast majority of opioids are used in developed countries. Their use has increased 
considerably in recent years, approximately doubling (in terms of morphine 
equivalents) between 2002 and 2007. Increases have been particularly steep for the 
synthetic and semi-synthetic opioids (International Narcotics Control Board, 2007). 
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Levels of opioid consumption in Canada, while somewhat below those in the United 
States, are among the highest in the world; on a per capita basis, Canada is second 
only to the United States in consumption of oxycodone and is the number one 
consumer ofhydromorphone. In 2006, Canada, with approximately 0.5% of the 
world's population, consumed 28% of the total global supply ofhydro.morphone 
(International Narcotics Control Board, 2007). Over 107 million doses of strong 
opioids, principally oxycodone, morphine, and hydromorphone, were dispensed from 
Ontario retail pharmacies in 2005 (lMS Health; table 1). This increased to 121 
million in 2006 and to 133 million in 2007. There are limited data on the numbers of 
users these sales data represent. Among Ontario respondents to cycle 1.1 of the 
Canadian Community Health Survey, however, approximately 6% reported past-
month use of "codeine, Demerol, or morphine" (unpublished data). 
Increased use of opioids over the past 10 or 15 years has been driven largely by 
increased prescription of opioids for pain management, although use of methadone in 
addiction treatment programs also rose over this period. Increases in opioid 
prescribing in North America coincided with the introduction and marketing of 
extended-release formulations such as OxyContin. Medications in these forms were 
initially believed to have limited potential for recreational use. This may have been a 
factor in the increase in physicians' willingness to prescribe strong opioids, and was 
certainly a cornerstone of some companies' marketing efforts (GAO, 2003; Van Zee, 
2009). These formulations do, however, retain the potential for recreational use, and 
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the sustained release features are trivially easy to bypass: Crushing or chewing tablets 
will cause the drugs they contain to be rapidly released. 
Epidemiology of opioid misuse 
In 1993, a report from the u.s. National Institute on Drug Abuse revi~wed existing 
epidemiological evidence on prescription medication misuse generally and concluded 
that "the vast majority of prescribed use of these drugs is conservative, 
therapeutically appropriate, and limited to short periods oftime". It went on to note 
that more than 95% of users reported having been prescribed the drugs they used, and 
that "consumer attitudes toward taking psychoactive prescription drugs are also 
conservative" (NIDA, 1993). 
During the 1990s, significant changes occurred in prescriptions of opioids and, 
arguably, in popular attitudes towards the use of analgesics and psychotropic 
medications. Opioid prescriptions, as noted, increased sharply. Although there is 
some evidence that the increase in opioid prescription in the first half of the 1990s did 
not immediately result in increased misuse (Joranson et aI., 2000), most indicators of 
non-medical use since that time suggest that it has grown in step with the total 
availability of opioids (e.g., Dasgupta et aI., 2006). Although some initial trials of 
extended-release opioid formulations suggested their potential for misuse was limited 
(GAO 2003), it is now clear that this is not the case. 
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A 2005 study of illicit users of opioids in 7 Canadian cities found that heroin was 
used by only 30%, and illegally-obtained methadone by only 9%. Instead, 
prescription drugs accounted for the majority of illicit opioid use, and appeared to be 
in the process of displacing drugs such as heroin (Fischer et aI., 2006). Patterns of 
use varied substantially between cities, with heroin predominating in yancouver and 
Montreal and other opioids in Edmonton and Quebec City. Among study participants 
from Toronto (n=141), 53% reported past-month heroin use, 42% hydromorphone, 
69% codeine, 31 % illegally-obtained methadone, and 84% "other opioids" (Fischer et 
ai. 2005). Similarly, in an ongoing study of 546 outpatients in substance abuse 
treatment in Toronto, Niagara, and Oshawa, 36% (194 of537 responding) reported 
past-year use of prescription opioids, while only 7.4% (40 of 535) had used heroin 
(Rush et aI., in preparation). 
Recreational use of opioids also appears to have become widespread among Ontario 
adolescents. 21 % of students surveyed in the 2007 Ontario Student Drug Use and 
Health Survey (OSDUHS) reported past-year non-medical use of a prescription 
opioid, with use somewhat more common in northern Ontario and less so in Toronto 
(Adlaf & Paglia-Boak, 2007). In the 2009 survey, this proportion fell slightly, to 18% 
(Paglia-Boak et aI., 2009). 40% of students who did report using prescription opioids 
in the past year did so on only one or two occasions (unpublished data). 
In the recently-released Canadian Youth Smoking Survey (YSS), conducted in 2006 
and 2007, 6.1 % of all Ontario secondary school students, and 8.5% of those in grade 
12 
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12, reported ever having "used painkillers to get high" (unpublished d~ta). Although 
comparable data for Canada are unavailable, treatment episodes for abuse of or 
dependence on prescription opioids increased 45% in the United States between 1994 
and 1999 (CPDD 2003: SAMSHA, 2001, 2002). 
Although all use of opioids without both a prescription and an appropriate, diagnosed 
medical condition is typically considered 'misuse' or 'abuse', recent research has 
shown that the distinction between medical and recreational users is often difficult to 
make. A recent study of opioid users in the rural United States reported that many 
people with legitimate prescriptions for pain also reported recreational use, while 
many illicit users reported use for analgesia (Havens et ai. 2008). Other studies have 
similarly noted that pain relief is one of the most frequently endorsed motives for the 
use of non-prescribed opioids (McCabe et aI., 2007). Differences between Ontario 
epidemiological surveys in estimates of opioid "misuse" suggest that this issue is a 
significant one; the YSS and the OSDUHS both surveyed the population of Ontario 
secondary school students during the same year, but, as noted, the YSS reported a 
much lower prevalence. This may be explained, in part, by the fact that the YSS 
asked about "[use of] painkillers to get high" (YSS 2007), while OSDUHS asked 
about use of any of several common prescription opioids "without a prescription or 
without a doctor telling you to take them" (OSDUHS 2009). 
Both legitimate and illicit use of prescription opioids are associated with age. Use 
without prescriptions has been shown in epidemiological studies to be most common 
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among younger people, particularly those under approximately age 25 (Manchikanti 
& Singh, 2008). Serious consequences, including overdose, are more commonly seen 
among men (e.g., Hall et al., 2008) and at somewhat greater ages, with mean ages of 
30 or somewhat more typical in studies of overdose fatalities (Hall et aI., 2008; 
Darke, 1996). 
Sources of opioids 
Opioid analgesics may be obtained by legitimate prescription, by forged 
prescriptions, from internet pharmacies, by prescriptions obtained by misleading 
physicians, by physicians knowingly prescribing opioids for non-medical use, or by 
theft from pharmacies or other facilities (Health Canada, 2006). Significant 
quantities are stolen. A recent study using data from 22 eastern American states, 
representing roughly half the national population, found that 1.8 million doses of 
strong opioids (fentanyl, hydromorphone, meperidine, methadone, morphine, and 
oxycodone) and 4 million doses of hydro cod one were reported stolen in 2003. 89% 
of these thefts were from pharmacies (Joranson & Gilson 2005). 
Most opioids used non-medically are ultimately obtained from physician 
prescriptions, however, either directly (by "doctor shopping" or by feigning or 
exaggerating physical health problems; Zacny et aI. 2003) or from other individuals 
who give away or sell their medications. There is some evidence that the latter 
pattern is predominant: A report on prescription opioid-related fatalities in West 
Virginia noted that only 44% of decedents had been prescribed the medication that 
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killed them, and only 29% had filled such a prescription in the previous 30 days, 
despite the fact that this is the maximum supply of schedule II drugs that may be 
dispensed in West Virginia (Hall et aI., 2008). Most respondents to epidemiological 
surveys who report using opioids without prescriptions also obtain them from friends 
or relatives (e.g., McCabe 2007), and this seems to be likewise true o~people in 
treatment for opioid dependence (Rosenblum et aI., 2007). Unlike illicit drugs, 
therefore, in which there is a large, global trade, most prescription opioids are 
obtained locally from physicians and pharmacists. 
Epidemiology of opioid overdose 
According to data from the Drug Abuse Warning Network (DAWN) (Substance 
Abuse and Mental Health Services Administration, 2002), which collects information 
from a representative American sample of emergency departments, medical 
examiners, and coroners, incidents involving opioid analgesics increased 83.5% 
between 1997 and 2002. More recent DAWN data have shown that overdose deaths 
resulting from the non-medical use of opioid analgesics now outnumber those due to 
heroin or cocaine (Paulozzi, 2006). Evidence from the same source has shown that 
ED contacts for opioid overdose are strongly correlated over time with the total 
amounts of opioids prescribed in the United States, and that the number of overdose 
incidents per unit of morphine equivalents prescribed is reasonably similar across all 
opioids (Dasgupta et aI., 2006). 
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There are limited data on the epidemiology of opioid overdose in Call1ida. A 
toxicological study of 251 hydromorphone-related deaths investigated by the 
coroner's office in Ontario between 1985 and 2003, however, reported that such 
deaths increased sharply over this period (Wallage & Palmentier 2006). Between 
1985 and 1991, there were no more than 2 known fatal cases ofhydro!llorphone 
poisoning per year. Between 1996 and 2000, there were approximately 20 annually, 
and in 2003 there were 63. 
Opioid-related harms, prescribing practices, care 
Several studies have linked poor prescribing practices with population-level 
indicators of harms, particularly overdose. Between 1985 and 1995, the United 
Kingdom had a substantially higher incidence of fatal methadone overdoses than 
other countries, and this is thought to have been largely the result of poor practice: 
During this period, methadone was commonly dispensed in substantial quantities for 
self-administration. The adoption of guidelines recommending supervised dosing -
in which most patients are required to come each day to a pharmacy or specialist 
clinic to receive methadone - in 1996 led to a substantial decline in mortality (Hall 
2000; Strang 2007). 
A more relevant example ofthe association between prescribing practices and opioid-
related problems is that ofOxyContin. Within a few years of its introduction in 1996, 
OxyContin had become a significant problem in certain, mostly rural, areas of the 
United States. The drug's widespread misuse was made possible by inappropriate 
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local prescribing. The number of prescriptions written by family physicians rose 
sharply in the late 1990s and early 2000s. This increase has been attributed to 
aggressive marketing efforts by OxyContin's manufacturer, Purdue Pharmaceuticals, 
which encouraged physicians to prescribe it for a wide variety of conditions (General 
Accounting Office, 2003). Primary care physicians, in particular, played an 
important role, coming to account for almost half of all prescribers of the drug (Van 
Zee, 2009). OxyContin, however, is only the most prominent example of a much 
more widespread increase in problems stemming from the expanded use of opioid 
analgesics. 
Geographical and demographic variation in risk of opioid poisoning 
Opioid poisoning is not uniformly distributed in the population. As with other 
substance-related problems, there are considerable differences between areas. 
Availability of these drugs, for example, may vary with jurisdiction or according to 
variations in practice. Epidemiological research in the United States has also shown 
that problematic opioid use varies markedly between states (e.g., Kuhn 2007). These 
between-state differences have been linked to differences in the overall levels of 
opioid prescribing, which have been shown to vary substantially (Paulozzi & Ryan, 
2006). 
Existing evidence from the United States suggests that opioid-related problems are, in 
general, more prevalent in rural areas (GAO 2003). Between 1999 and 2004, fatal 
narcotic drug poisonings rose by 248% in the most rural areas of the U.S.; by the end 
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of this period, the incidence of fatal drug poisoning in these areas wascomparable to 
that in major cities, and mortality from prescription opioids specifically was higher 
than in any other urbanicity-based census category. A review of drug and alcohol-
related poisoning deaths in New Mexico from 1994 to 2003 similarly found that, 
although large cities had the highest overall mortality, deaths involvins prescription 
medications were most common in rural areas (Centers for Disease Control and 
Prevention 2005). This association was particularly marked for opioids. 
To date, major Canadian population health surveys have not collected detailed 
information on the nonmedical use of prescription drugs; as a result, there is limited 
information available on the epidemiology of opioid misuse in Ontario. The only 
available estimates come from OSDUHS, which samples only junior high and 
secondary school students and which added questions on prescription opioid use only 
in 2007. Its finding of higher levels of non-medical use in northern Ontario, however, 
agrees with American reports that problems have been concentrated in rural areas. 
Several explanations for the increased prevalence of prescription opioid-related 
problems in rural areas have been proposed. Heroin and other illicit drugs may be 
less easily available outside of urban centres, which has suggested to some the 
existence of an 'untapped market' (GAO, 2003). Although fatal overdoses and severe 
dependence are sometimes concentrated in large urban centres (e.g., Vancouver's 
lower east side), problems related to alcohol and illicit drug use, broadly defined, 
appear to be more prevalent in mid-sized cities and in rural areas (Veldhuizen et aI., 
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2006). It is conceivable that the higher levels of opioid-related problems in rural 
areas are, therefore, due in part simply to a higher propensity to use or misuse alcohol 
and drugs in general. It has been noted that the prevalence of opioid and alcohol-
related problems were elevated in Appalachia long before the appearance of 
OxyContin (GAO, 2003). 
Variations in opioid poisoning in Ontario 
Several factors, then, might give rise to geographical differences in the incidence of 
opioid overdose. These include differences in the prevalence of health conditions for 
which opioids are legitimately prescribed; in the quality of medical care provided 
(e.g., inappropriate prescription, lax monitoring); and in background levels of 
problematic substance use and of risk factors for problematic substance use. 
There is some evidence that specialist physicians are better-placed than general 
practitioners to treat chronic pain conditions and to manage opioid prescriptions. A 
Danish study showed that care at a specialist clinic resulted in improvements in 
functioning and subjective pain, while care dispensed by general practitioners after 
specialist assessment was significantly less effective (Becker et aI., 2000). Non-
specialists may also be somewhat more likely to prescribe inappropriate medications 
generally (Goulding 2004; Nissen 2001), and opioids may be particularly 
problematic. 
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Similarly, a recent American survey concluded that guidelines, including those on 
opioid prescription, were frequently violated in primary care (Di Iorio et aI., 2000). 
Many primary care physicians have doubts about their own expertise in the area of 
pain management; in a recent British survey, only 11 % of practitioners had 
specialized training in pain management, and 95% of the remainder f~lt their medical 
school or primary care training in this area was inadequate (Hutchinson et al., 2006). 
Another potential link between rural residence and misuse of opioids, however, 
concerns the availability of medical services. In Canada, specialist physicians are 
heavily concentrated in major cities, while general practitioners provide the majority 
of medical care in rural areas (Pong & Pitblado, 2005). Despite consistent efforts by 
the provincial government to attract physicians to rural and northern areas, these parts 
of the province are under served. Among Ontario's 49 counties, the number of 
specialist physicians per 100,000 population varies from a low of 0 to a high of over 
250 (table 2). These numbers may also obscure a more serious shortage in remote 
areas, since the impact of the relatively low numbers of specialists in some southern 
Ontario regions may be ameliorated by the ease oftravel to Toronto or other cities for 
specialist consultations. General practitioners in more remote regions typically serve 
large numbers of patients scattered across large geographical areas. Since specialists 
are scarce, general practitioners in these practices are typically responsible for a 
broader spectrum of medicine than their urban colleagues (CIHI, 2005). 
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The lack of easily accessible care in rural and remote parts of the province is reflected 
in statistics on hospitalization rates for conditions that can usually be successfully 
treated in community settings (known as ambulatory care sensitive conditions, or 
ACSCs). ACSCs include diabetes, asthma, hypertension, substance dependence, and 
mood or anxiety disorders that are seldom severe enough to merit hospitalization 
(e.g., dysthymia, panic disorder, specific phobia) (Statistics Canada, 2004). High 
levels of hospital admissions for these conditions are thought to indicate limited 
access to community-based health services, since appropriate management will 
usually prevent them from becoming severe enough to require inpatient care. In 
2004-2005, age standardized rates of hospitalizations for ACSCs per 100,000 varied 
substantially across Ontario's local health integration networks (LHIN s), from 223 in 
Central to 658 and 694 in the North East and North West LHINs, respectively (CIHI, 
2007). 
Table 2. General practitioner and specialist availability (physicians per 100, 000 
population) in Ontario in 2005 by census division. 
Specialists Non-specialists Specialists per Non-specialists per 
Census Division (n) (n) 100K 100K 
Algoma 68 112 58 95 
Brant 79 99 65 81 
Bruce 2 49 3 76 
Cochrane 30 93 36 111 
Dufferin 22 40 42 76 
Durham 274 332 51 62 
Elgin 41 57 49 68 
Essex 251 248 65 65 
Frontenac 359 226 254 160 
Grey 62 83 68 91 
Haldimand-
Norfolk 14 61 13 57 
Haliburton 1 12 6 77 
Halton 258 352 63 86 
Hamilton-
Wentworth 854 432 172 87 
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Specialists Non-specialists Specialists per Non-specialists per 
Census Division (n) (n) 100K 100K 
Hastings 84 101 66 79 
Huron 11 47 18 79 
Kenora 19 89 30 141 
Kent 43 64 40 59 
Lambton 70 75 55 59 
Lanark 20 71 32 112 
Leeds & 
Grenville 47 75 48 77 
Lennox & 
Addington 3 38 8 95 
Manitoulin 0 19 0 147 
Middlesex 732 380 177 92 
Muskoka 23 69 42 125 ~ Niagara 251 285 60 68 
Nipissing 68 77 81 92 
Northumberland 20 56 25 71 
Ottawa-Carleton 1381 969 174 122 
Oxford 33 64 33 63 
Parry Sound 7 37 17 92 
Peel 585 770 54 72 
Perth 52 62 70 84 
Peterborough 116 127 90 98 
Prescott & 
Russell 24 74 31 94 
Prince Edward 4 26 16 103 
Rainy River 2 23 9 105 
Renfrew 28 77 29 80 
Simcoe 208 329 52 82 
Stormont 
Dundas & 
Glengarry 53 107 48 97 
Sudbury D.M. 1 12 5 54 
Sudbury R.M. 164 143 105 91 
Thunder Bay 129 143 86 95 
Timiskaming 10 42 30 124 
Toronto 
Metropolitan 4261 2835 171 114 
Victoria 24 47 33 65 
Waterloo 285 363 62 79 
Wellington 120 169 62 87 
York 443 580 55 72 
There are thus a number of reasons to suspect a link between incidence of opioid 
overdose and availability of specialist medical care. As noted, opioids may be more 
likely to be inappropriately prescribed by primary care providers in general, and this 
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may be particularly true in areas where a single provider is responsible for a large 
number of clients and has limited options for specialist referral. The relative 
inaccessibility of specialist consultations may mean that diagnosis and effective 
treatment of painful conditions is more difficult; some imaging services, for example, 
are available only at a relatively small number of specialized centres., This may lead 
to long-term management with opioids when other treatments might be possible. 
Furthermore, distances between providers and patients may also prevent careful 
management of opioid and other medications. It may be impractical, for example, for 
a provider in a remote area to see a client as frequently as would be ideal. All of 
these issues may lead to higher levels of opioid use, and also to a greater potential for 
misuse or diversion. 
These issues may also increase risks of other conditions that frequently contribute to 
overdose. The same factors affecting management of opioid prescriptions may lead 
to inappropriate or poorly-managed use ofbenzodiazepines, which, as described 
above, frequently contribute to overdose. The high level of ACSCs in these parts of 
the province may also increase both need for opioids and risk of overdose. 
Inadequately managed diabetes, for example, may lead to diabetic neuropathy, a 
painful condition that may require treatment with opioids. At the same time, other 
conditions, such as liver problems arising from alcohol use or hepatitis, may increase 
susceptibility to overdose, and these are sometimes avoidable with appropriate 
medical care. 
23 
Study purpose 
This study has two aims. The first is to describe the epidemiology of opioid 
poisonIng in Ontario in recent years, with attention to trends over time and 
demographic differences in event rates. The second is to examine a possible link 
between the availability of specialist care and the rate of opioid POiSOl}ing. As noted, 
previous work has shown that opioid analgesic availability is a function of local 
prescribing practices, and that these, in turn, often vary sharply between regions. 
There is also evidence that specialists are better able to manage chronic pain (Becker 
et aI., 2000), are more likely to follow prescribing guidelines (Nissen et aI., 2001; 
Goulding et aI., 2000), and are more successful in avoiding medication-related harms. 
The hypothesis examined in this study is therefore that low availability of specialist 
physicians is associated with a high incidence of prescription opioid poisonings. 
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METHODS 
Data 
Data on opioid poisoning episodes were drawn from the National Ambulatory Care 
Reporting System (NACRS), a database maintained by the Canadian Institute for 
Health Information (CIHI) which includes episodes of hospital- and c?mmunity-
based ambulatory care. Variables available in the NACRS database are listed in table 
3. For this project, we obtained records of all emergency department (ED) 
admissions in the province of Ontario between April 2002 and March 2006 (i.e., 
fiscal years 2002 to 2005) for which opioid poisoning was listed as a diagnosis. 
Diagnosis was determined from the ICD-IO codes recorded for treatment contact; 
those codes corresponding to opioid poisoning for the purposes of this analysis are 
listed in table 4. Records were included irrespective of the presence of other 
diagnoses, even if opioid overdose was not the first condition listed. The most 
common co-occurring diagnoses are given in table 8, while the most common 
primary diagnoses in cases where opioid poisoning was listed as a secondary 
diagnosis are given in table 9. All conditions accounting for 1 % or more of the latter 
records concern either poisoning with other substances (notably acetaminophen and 
benzodiazepines) or mental health conditions that may be associated with increased 
risk of substance abuse or deliberate self-harm. Records flagged as 'multiple contact 
records', which occur when an individual is seen by multiple providers in the context 
of a single event, were excluded. Poisonings resulting from use as intended are 
excluded on conceptual and practical grounds, for reasons described below. 
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Information on total opioid prescriptions dispensed from Ontario pharmacies was 
obtained from IMS Health. 
Table 3. NACRS variables. 
Patient ID 
Fiscal year 
Patient's birth year 
Patient's gender 
Patient's FSA 
ICDIO diagnosis codes (up to 25) 
"Coding class" 
Admission date 
Discharge date 
MCR flag ("to indicate multiple contact records in NACRS") 
Variables 
The NACRS dataset obtained includes ICD-I 0 codes providing information about the 
circumstances in which each poisoning event occurred. Virtually all contacts were 
accounted for by four types of events: Complications of care due to use of analgesics 
(lCD-IO code Y45); intentional self-poisoning (X60-X64); poisoning with 
undetermined intent (YIO-YI4); and accidental poisoning (X40-X44). 
Table 4. 
T40.2 
T40.3 
T40.4 
T40.6 
ICD-J 0 diagnostic codes for opioid overdose. 
Poisoning by other opioids (codeine, morphine, oxycodone, 
hydrocodone,hydromorphone) 
Poisoning by methadone 
Poisoning by other synthetic narcotics (fentanyl, pethidine) 
Poisoning by narcotic, not elsewhere classified (other, unknown, or 
unidentified opioid) 
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Complications of care 
Complications of care are adverse events occurring when medications are taken as 
prescribed. CIRI coding guidelines state that this event type should not be associated 
with opioid poisoning codes (CIRI, 2006). In the dataset received, however, there 
.. 
were 1138 admissions with this combination of codes. These records were excluded 
" 
from the analysis for several reasons. The most important of these is that the included 
records are likely to represent an unknown proportion of all contacts for adverse 
events. The number ofthese events declined substantially over time, from 360 in 
FY2002 to 221 in FY200S, while all other types of events increased in number. In 
the absence of very significant, province-wide improvements in the management of 
opioid medications, this strongly suggests a gradual shift in coding practices. The 
included data are also not likely to be a random subset of all contacts for adverse 
events, as their inclusion may have been influenced by differences in practice 
between hospitals or analysts. 
Adverse events occurring when medications are taken as prescribed are also perhaps 
less likely than other contacts to represent serious overdoses. Mild overdoses or 
various opioid side effects might lead to an ED visit, and these may have erroneously 
been recorded as 'poisonings'. Finally, the exclusion of adverse events results in a 
dataset that should consist entirely of events arising from misuse (principally 
accidental overdoses and incidents of self-harm). Although inclusion of adverse 
events would result in a more complete picture of the public health consequences of 
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prescription opioid use, the set of ED contacts resulting from misuse thus remains 
conceptually meaningful. 
Intentional self-poisonings include events where the overdose was the result of a 
deliberate attempt at self-harm. Accidental poisonings include overd<?se due to 
misuse, but also overdoses occurring due to errors in use of a prescribed medication 
on the part of a patient, health care provider, or other individual. Events of 
undetermined intent include all those incidents where an external cause could not be 
identified. A small number of events received multiple or no flags, and a very small 
number received other designations (e.g., assault). These were combined with events 
of undetermined intent to form an 'undetermined or other' category. 
Results are therefore reported for three types of events: Accidental overdoses; 
intentional self-poisonings; and events of undetermined or other intent (including 
those with no, multiple, or other flags). The multivariable analysis focuses on the 
total number of events ascribed to accidental overdose or of undetermined or other 
intent. This approach follows existing work (e.g., Paulozzi, 2006) and is intended to 
capture events resulting from recreational use. 
Population-level data 
PopUlations, age distributions, and socioeconomic status indicators are available from 
census tables and postal code databases published by Statistics Canada and were 
obtained through the University of Toronto's data library. As these results are 
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available for the census years of2001 and 2006, while the study data ~over the 
intervening period, it was necessary to impute populations for each of 10 age/sex 
groups in each forward sortation area (FSA). This was done by calculating the rate of 
growth between the two censuses and using this to estimate values for each year 
between these points. The rate of growth between two (non-zero) me~surements is 
given by the formula g = [(h/tdlln)] - 1, where n is the number of intervening time 
points. The population estimate at each time point is then given by the formula tn = t1 
The analysis includes 5 categories for age (0 to 14, 15 to 24, 25 to 49,50 to 64, and 
65 and older) and two for sex (male and female), for a total of 10 groups. NACRS 
data were collapsed to obtain a count of events of each type by FSA and age/sex 
category, while population counts for each of these groups was obtained as described 
from census data. 
Table 5. Income, rurality, overdose rates, and physician availability in Ontario 
(means). 
Median household income 
Proportion rural 
Illicit drug or alcohol poisoning event rate (annualized, per 100,000) 
Specialist physicians per 100,000 
General practitioners per 100,000 
Independent variables 
$60,455 
15.3% 
12.0 
84.7 
92.6 
Age and sex. As noted, substantial demographic differences in rates of opioid 
overdose have been previously reported, and are universally found in population-
based investigations of harms related to substance use. 
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FSA-Ievel variables 
The multivariable analysis includes 5 variables measured at the FSA or census 
division level. Provincial averages for these variables are presented in table 5. 
Rurallurbanforward sortation area. Forward sortation areas are classified as either 
urban or rural; rural FSAs have a zero in the second position of the three-letter FSA 
identifier (e.g., POL). Although this distinction is made to indicate the means of mail 
delivery in each area, and does not reflect any more detailed information on 
population density, it can be expected to reflect a fair distinction between urban and 
rural areas, and has the further advantage of providing a binary indicator at the main 
level of analysis. 55 of the 505 populated FSAs included in the analysis, representing 
15.3 % of the provincial population, were rural. 
Median household income. This is a general measure of regional socioeconomic 
status (SES), which is known to be important in studies of substance-related harms. 
The Canadian census includes several potential measures of SES, including 
unemployment rate, proportion of households below a "low income" threshold, and 
the proportion of individuals with various levels of education. Median household 
income was selected because it is a continuous measure that will reflect the general 
level of prosperity or poverty within the region, and because it accounted for more 
model variance than most other possibilities. Education measures proved at least 
equally statistically significant in preliminary models, but were also more strongly 
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correlated with the availability of specialist physicians, and so were a"oided partly in 
the interests of avoiding collinearity. 
Background incidence of overdose. Background rates of ED visits for non-opioid 
recreational drug overdoses were obtained from the same NACRS dataset used to 
derive data about opioid poisonings. This variable is the rate per 100,000 population 
of all poisonings due to the use of cocaine (lCD 10 code T405), cannabis (T407), 
ethanol (T510), or hallucinogens (T408, T409). Psycho stimulants other than cocaine 
(e.g., MDMA, methamphetamine, amphetamine) were not included because the ICD-
10 code under which they fall (T436) includes prescription stimulants such as 
methylphenidate, the use of which might be influenced by the same factors (including 
availability of specialist care) as the primary outcome. 
Availability of general and specialist physician care. Data on the numbers of 
specialist and nonspecialist physicians practising in Ontario's regions were obtained 
from the Ontario Physician Human Resources Data Centre (OPHRDC) report '2005 
Physicians In Ontario by Specialty and Region' (OPHRDC, 2006). The present 
analysis uses counts of physicians at the census division (CD) level, divided by the 
CD population and multiplied by 100,000 to obtain a measure of specialist and 
nonspecialist physicians per unit population. Although these data reflect counts only 
in calendar year 2005, they are likely to be generally representative of the distribution 
of physicians over the study period as a whole; only substantial shifts in this 
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distribution between 2002 and 2005 would pose a threat to the validity of this 
measure. 
Ontario includes 49 census divisions. In the 2006 census, these units varied in size 
from approximately 13,000 (Manitoulin) to 2.5 million people (metropolitan 
Toronto), with a mean of 248,000 and a median of 103,000. Census divisions cover 
geographical areas substantial enough for an aggregate measure of availability to be 
meaningful, but numerous enough for there to be adequate variability. Postal units, 
however, do not correspond to Statistics Canada regions. Using a file linking postal 
codes to census regions obtained from DMTI Spatial (DMTI, 2004), it was 
determined that 109 of the 512 FSAs with non-zero populations, representing 
approximately 28% of the provincial population in 2006, did not fall within a single 
CD. In these cases, availability was calculated as an average of the CDs overlapping 
the FSA, weighted by the population within each CD. This process resulted in an 
exposure variable with a total of 135 levels. This process was chosen as a reasonably 
simple and conceptually acceptable way of obtaining a measure of physician 
availability. Although there are methods of spatial analysis that provide alternative 
techniques for approaching problems of this kind (e.g., Best et aI., 2000), these are 
complex, of uncertain value, and can complicate the interpretation of results. 
32 
Analysis 
Descriptive epidemiology of opioid poisoning in Ontario 
The first part of the analysis concerns the number of poisoning events recorded, their 
circumstances, trends over time, and demographic differences. In most cases, event 
rates are preferred to incidences. Event rates are calculated by dividiIJ.g the total 
numbers of events by the appropriate interpolated census population. Incidence is 
similar, but the numerator represents the number of individuals presenting within 
each period. Event rates are reported for each of 10 demographic categories, as well 
as for the province as a whole and for each year. Incidence is not calculated for 
individual types of events largely because the determination of the population at risk 
becomes somewhat arbitrary and the resulting number correspondingly less 
meaningful: A single individual with 3 ED visits within a year will be counted once 
in the calculation of overall annual incidence, but might appear in each of three event-
type-specific numerators. Cases where multiple event types are recorded present 
further complications. In this context, event rates are clearer and more meaningful, as 
well as more accurately reflecting the clinical and public health burden of opioid 
pOlsomng. 
Regression modeling 
The multi variable analysis is performed on three outcomes: 1) the total event rate; 2) 
the rate of accidental events plus the rate of events of undetermined or other intent; 
and 3) the rate of incidents of self-harm. Modeling is done using a mix of Poisson 
and negative binomial regression. 
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Poisson regression is a type of generalized linear model appropriate to count 
outcomes. Observed counts are assumed to result from Poisson processes, in which 
events occur independently and continuously. Counts of events resulting from such a 
process follow a Poisson distribution, which is characterized by a single parameter (A) 
which is equal to both the mean and the variance. Poisson regression models the log 
of the expected count as the function of an intercept and a vector of coefficients for 
predictor variables. Where the 'exposure' (i.e., the denominator of the event rate) 
varies between units of the analysis, the model also includes an offset. The offset is 
the log of the exposure (in epidemiology, typically people, person-years, or time) and 
receives a coefficient constrained to equal 1. The general form of a Poisson model 
for rates is thus: 
10g(E(Y)) = log(exposure) + a + bx 
Equivalently, the expected count is: 
E(Y) = exp(log( exposure) + a + bx) 
A common problem with Poisson models is that observed distributions of counts do 
not follow a strict Poisson distribution, but rather have a variance greater than the 
mean. This situation, known as overdispersion, can be interpreted as the result of 
unknown influences on the underlying process which result in wider-than-expected 
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variation in rates (StataCorp, 2009). Negative binomial regression is an alternative to 
Poisson regression that addresses this problem by introducing a model parameter (a) 
to correct for overdispersion (alternatively, Poisson regression can be defined as a 
special case of negative binomial regression in which a is fixed to zero). This extra 
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parameter allows the negative binomial distribution to take on a much, greater variety 
of forms. 
In the present analysis, Poisson models were fit initially and were tested for 
overdispersion using estat gofin Stata, which compares the fit of a Poisson to that of 
a negative binomial model and performs a likelihood ratio test to determine whether 
the inclusion of a dispersion parameter significantly improves model fit (StataCorp, 
2009). Where significant overdispersion was present, negative binomial regression 
was then used. In the results presented, the time-only models were fit using Poisson 
regression; all others used negative binomial regression. All models were adjusted 
for the population at risk for each unit of the analysis by specifying the appropriate 
population variable as the relevant exposure. 
Both Poisson and negative binomial regression yield incidence rate ratios (IRR). In 
the case of binary predictor variables, an IRR may be interpreted as the rate in the 
"exposed" group divided by the rate in the "unexposed" group. For continuous or 
ordinal variables, the IRR represents the change in the outcome rate associated with 
an increase of 1 in the predictor. The expected rate for a given set of variable values 
can be obtained from the formula r = exp(x) / (1 +exp(x)), where x represents the 
35 
solution to the regression equation for the values of interest. This approach was used 
to generate the graphs of predicted rates presented in figures 3 and 4. 
General approach 
" The rates of each of the three event types defined above are analyzed !Ising the 
following series of models: 
1. Event rate = f(time) 
2. Event rate = f(age, sex) 
3. Event rate = f( age group, sex, urban/rural, median FSA income, rate of drug 
overdose) 
4. Event rate = f( age group, sex, urban/rural, median FSA income, rate of drug 
overdose, specialist availability, nonspecialist availability) 
Model 1 tests for change in the event rate over time. Models 2 through 4 are nested 
models. Model 2 explores variation by age and sex, while model 3 introduces the 
FSA-Ievel study variables. Model 4 adds the physician availability variables in order 
to assess their independent effects on the event rate. It should be noted that the effect 
for time is omitted from models 2 through 4, and that these models thus examine 
variation across the other variables throughout the study period as a whole. 
Fractional polynomials 
In this analysis, specialist physician availability is modeled as a continuous variable. 
Although the study hypothesis posits an inverse association between specialist 
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availability and the rate of prescription opioid poisoning, it is not certain that the 
independent association between these two variahles, if one exists, is linear at the log 
scale. An examination of the bivariate relationship between the outcomes and the 
availability variable (e.g., figure 2) suggested that it was not. This, however, is the 
only detectable possibility for continuous variables entered into an orqinary Poisson 
or negative binomial model. 
In order to test for a possible non-linear effect for the availability of specialist 
physicians and to fit parameters reflecting such a relationship, I use the method of 
fractional polynomials (Royston & Altman, 1994). This approach involves fitting 
models that include different transformations of the original variable and 
combinations thereof, and selecting the model which best fits the data. The fractional 
polynomials procedure used fits powers of -2, -1, -0.5, 0.5, 1,2,3, and the natural 
logarithm. As implemented in Stata 11, models with all possible combinations of 
terms are fitted and their total deviance compared. Details of this process are 
available in Stata documentation (StataCorp, 2009). In the present analysis, I fit 
models of up to 2 terms. 
Effects for other continuous covariates were also assessed for linearity. This was 
done using FP in models including only the covariate of interest. Attempts to fit these 
terms simultaneously in the full model would be problematic because of the 
extraordinarily large number of models that would need to be tested and associated 
problems of computational tractability and complications in questions of statistical 
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inference arising from large numbers of tests. In the case of nonspecialist 
availability, a statistically significant improvement (p=0.04) was obtained for a term 
raised to the power of -2, but the practical improvement in model fit was small and 
appeared not to justify the added complexity. A linear model was therefore used. For 
median family income, the linear effect was optimal, while a square n:~ot 
transformation was applied to ED contacts for alcohol or illicit drug poisoning. 
Adjustment for clustering of observations 
In models 2, 3, and 4, for which data are aggregated to the level ofwithin-FSA 
age/sex groups, variance estimation uses the 'cluster' option in Stata. This takes into 
account shared variance within FSAs. FSA of residence does not otherwise appear in 
the models used. Investigations ofthis approach have found that, in addition to 
improving robustness of standard errors, it presents minimal risks when the number 
of clusters is greater than 50 (Kezdi, 2004). 
All statistical analyses were performed using Stata 11 (StataCorp, 2009), with the 
exception of frequency distributions, which were calculated using a Microsoft Access 
database. 
Methodological issues: Statistical testing of 'census' data 
The data used in this analysis represent not a sample, but the total number of observed 
events for the entire population of interest. Event counts and rates are therefore 
reported without confidence intervals. The analysis does, however, include 
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significance tests for changes over time and for associations between variables. The 
reason for this is that the purpose of the analysis IS not to uncover variation in rates, 
but to test for changes in or influences on the underlying processes that give rise to 
opioid poisoning events. The question is therefore not whether there are differences 
in rates between subpopulations or over time, but whether this variatio.n reflects real 
differences in the likelihood of these events occurring. Despite the fact that they 
represent a population, therefore, the observed data are treated as a sample of all 
possible outcomes. 
Methodological issues: Limitations of ecological analysis 
This analysis is an ecological one, in that it tests for an association between a region-
level characteristic and the sum or average of many individual outcomes. This type 
of analysis is valuable in situations, such as this one, where alternative designs are not 
practical and where regional-level results are of interest, but it has a number of 
significant limitations. The two most important of these are the 'ecological fallacy' 
and the 'modifiable unit area problem'. The ecological fallacy refers to problems 
with drawing conclusions about individual-level characteristics from group-level 
measurements. A common example of this issue is the correlation between wealth 
and obesity, which is positive when variation between countries is considered but 
tends to be inverse in single-country, individual-level data. In the present context, 
there may be important geographical differences that are influencing the apparent 
association between availability of care and opioid poisoning rates. The modifiable 
unit area problem refers to errors in statistical inference that can arise when spatial 
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data are aggregated. The essential issue is that redrawing boundaries between areas 
can cause observed correlations, or multiple regression coefficients, to vary 
substantially. 
These issues affect the majority of ecological analyses. In the present, context, there 
are no practical alternatives to the analysis done, in the absence of considerably more 
detailed data than are available. The relatively large number of units of analysis may, 
moreover, provide some protection from these issues. 
Single-level v. multilevel models 
Populations at risk and counts of events are aggregated to the level of age/sex groups 
within FSAs, and the nesting of these records within FSAs is taken into account, as 
noted, by the specification of FSAs as clusters in the analysis. This approach does 
not, however, explicitly model FSA-Ievel differences in the processes giving rise to 
poisoning events. This could be done using mixed effects models, which would 
permit the inclusion of random effects. A random intercept at the FSA level in such a 
model would make it possible to model this variation, while random effects for 
predictors could take into account between-FSA differences in their effects. 
To evaluate this approach, a mixed effects Poisson model was fit for the final model 
of total events, with a random intercept at the FSA level. The random effect 
parameter was substantial (beta=0.425, SE=0.02), indicating the existence of 
considerable regional variation otherwise unaccounted for in the analysis. Parameter 
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estimates for fixed effects, however, were very similar to those obtainyd from the 
single-level model, with the majority within 10% of the single-level estimates and 
none differing by more than 15%. It is also not certain that results from the mixed 
effects Poisson model are more accurate than those from the single-level negative 
binomial model, as the former did not take overdispersion into accoun}. Given that 
the explicit modeling of FSA-Ievel effects was not a goal of the analysis, that the 
improvements in accuracy are uncertain, and that a multilevel approach would add 
considerable complexity to the analysis and to the interpretation of results, therefore, 
single-level models were used throughout the analysis. 
Results 
Descriptive epidemiology 
Between April 2002 and March 2006, there were 6283 ED contacts for opioid 
poisoning arising from incidents of self-harm, accidental overdose, or of other or 
undetermined causes. These visits were made by 5647 different individuals. 1962 
events (31 %) were judged to be due to accidental overdose and 2764 (44%) to 
intentional self-harm. For 1475 (23.5%) events, intent was recorded as 
'undetermined'. The remaining 82 events received multiple, other, or no event codes. 
For the purposes of the analysis, the 1557 events in the latter two groups were 
combined into a single 'undetermined or other' category. 1138 contacts in the data 
received were due to complications of care and were excluded from further analysis. 
Event counts and rates are presented in table 6. 
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The total number of events rose each year, from 1250 in FY2002 to 1816 in FY2005. 
Event rates are given in table 6 and are plotted in figure 1. Annual incidence for the 
province rose from 10.2 per 100,000 in FY2002 to 14.3 per 100,000 in FY2005. This 
corresponds to an overall increase of 40%, or an annualized increase of 11.8%. 
• 
Between FY2002 and FY2005, the total number of events rose 30% f9r self-harm, 
56% for undetermined or other, and 60% for accidental overdose. Event and 
incidence rates varied substantially by age, peaking among people aged 25 to 49, but 
were very similar for men and women (tables 7a and 7b). d I 
There was marked variation between age groups and sexes in the types of events 
recorded. Events occurring in women were more likely to be deemed the result of 
intentional self harm, while events of undetermined intent were somewhat more 
common among men and accidents were equally common in both sexes. Accidental 
overdoses predominated among children under 15. Variation among age/sex groups 
was generally highly significant (table 12). 
Table 6. Total events and events per unit p..op"ulation, by year. 
FY2002 FY2003 FY2004 FY2005 
Opioid poisoning events 
Accidental 373 459 528 602 
Undetermined or other 291 388 424 454 
Total accidental, undetermined, or other 664 847 952 1056 
Self-harm 586 708 710 760 
Total 1250 1555 1662 1816 
Events per 100,000 population 
Accidental 3.2 4.0 4.5 5.1 
Undetermined or other 2.5 3.3 3.6 3.8 
Total accidental, undetermined, or other 5.7 7.3 8.1 8.9 
Self-harm 5.1 6.1 6.0 6.4 
Total 10.9 13.4 14.1 15.2 
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Table 7 a. Opioid poisonings by age and fiscal year for men (events per 100,000 
p"op"ulation). 
EventT~~e o to 14 15 to 24 25 to 49 50 to 64 65+ 
FY2002 
Accident 3.5 2.2 3.5 2.5 4.1 
Self-harm 5 4.2 7.7 4.2 1.7 
Undetermined or 
other 5 1.9 4.3 1.8 0.9 
Total 3.8 8.3 15.6 8.4 6.7 
FY2003 
Accident 2.4 3.6 4.0 2.9 5.5 
Self-harm 5 6.0 9.1 4.3 0.7 
Undetermined or 
other 5 3.6 5.9 3.0 2.1 
Total 2.5 13.1 19.0 10.3 8.3 
FY2004 
Accident 2.0 3.6 5.6 4.1 3.9 
Self-harm 5 5.7 9.9 4.6 ' 2.5 
Undetermined or 
other 5 4.8 6.5 3.6 2.3 
Total 2.3 14.1 21.9 12.2 8.7 
FY2005 
Accident 2.8 4.4 6.5 4.0 6.0 
Self-harm 5 6.8 8.9 4.6 1.7 
Undetermined or 
other 5 3.1 6.8 3.5 2.3 
Total 3.3 14.3 22.3 12.1 9.9 
S Suppressed due to low number of events. 
Table 7b. Opioid poisonings by age and fiscal year for women (events per 100,000 
l!..0l!..ulation2-
EventT~~e o to 14 15 to 24 25 to 49 50 to 64 65+ 
FY2002 
Accident 1.6 3.3 2.8 2.8 4.9 
Self-harm 0.5 9.3 7.8 4.5 1.3 
Undetermined or 
other 5 3 3.2 3 1.9 
Total 2.3 15.6 13.8 10.3 8 
FY2003 
Accident 2.5 4.5 3.9 4.1 4.8 
Self-harm 0.9 11.5 9.6 5.2 1.3 
Undetermined or 
other 5 3.6 4 2.3 2.9 
Total 3.5 19.6 17.5 11.6 8.9 
FY2004 
Accident 2.5 3 4.7 4.4 6.6 
Self-harm 1 8.5 9.2 5 0.8 
Undetermined or 
other 0.4 3.4 3.6 3.4 2.2 
Total 3.9 15 17.5 12.8 9.6 
FY2005 
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Accident 1.1 4.4 5.1 4.9 6.9 
Self-harm 1 9.7 10.4 5.7 2.1 
Undetermined or 
other 5 4.1 4.3 4.3 2.1 
Total 2.4 18.3 19.9 14.9 11.1 
S Suppressed due to low number of events. 
" 
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Figure 1. Opioid poisonings per 100,000 population by year and cause. 
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As noted, ICD-10 includes four codes for opioid poisonings (table 4), but, with the 
exception of methadone, does not provide information on specific drugs. Across the 
study period as a whole, 3788 (60%) events were coded as 'other opioids', 1572 
(25%) as 'narcotics not elsewhere classified', 746 (12%) as methadone, and 268 (4%) 
as 'other synthetic narcotics'. Multiple opioid drug classes were recorded in 89 
(1.4%) of events. 
Diagnoses indicating poisoning due to substances other than opioid analgesics, 
defined as the presence of one or more other ICD-1 0 codes between T36 and T50 
("poisoning by drugs, medicaments and biological substances"), were present in 2215 
(35%) events. The inclusion of alcohol poisoning (T51 0, "toxic effects of ethanol") 
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increases this total to 2298 (37%). 310 (5%) events involved opium, heroin, cocaine, 
cannabis, or hallucinogens such as LSD or psilocybin (lCD-10 codes between T400 
and T409, excluding prescription opioid codes) and 105 (1.7%) included 
psycho stimulants other than cocaine (T436). 434 (7%) contacts had diagnoses of 
poisoning due to antidepressant or antipsychotic medications. Of thes,e, 
antidepressants were noted in 361 (6% of total) events and antipsychotics in 105 
(1.7%). A corresponding figure for mood stabilizers could not be obtained because 
the relevant ICD-l 0 codes largely do not permit the separation of these drugs from 
(other) anticonvulsant and sedative/hypnotic medications. The most common specific 
drug-related diagnostic codes recorded were those indicating poisoning due to 
benzodiazepines (13% of cases), acetaminophen (12%), and cocaine (4%). A list of 
specific codes and frequencies is presented in table 7. 
Table 8. Most common non-opioid-related ICD-J 0 diagnoses among feople 
presenting with opioid poisoning (all where proportion of total> J %) . 
ICD-10 
code 
T424 
T391 
F329 
T405 
T432 
T510 
T430 
F100 
T509 
T393 
T450 
T436 
T407 
T435 
F101 
F432 
T426 
Description 
Poisoning: Benzodiazepines 
Poisoning: 4-Aminophenol derivatives (acetaminophen) 
Depressive episode, unspecified 
Poisoning: Cocaine 
Poisoning: Other and unspecified antidepressants 
Toxic effects of ethanol 
Poisoning: Tricyclic and tetracyclic antidepressants 
Acute intoxication 
Poisoning: Other and unspecified drugs and substances 
Poisoning: Other NSAIDs (excludes ASA, acetaminophen) 
Poisoning: Antiallergy and antiemetic drugs 
Poisoning: Psychostimulants with abuse potential (excludes 
cocaine) 
Poisoning: Cannabis and derivatives 
Poisoning: Other and unspecified anti psychotics and 
neuroleptics 
Harmful use of psychoactive substances 
Adjustment disorders 
Poisoning: Other antiepileptics and sedative-hypnotic drugs 
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Occurrences 
(%) 
812(13) 
730 (12) 
329 (5) 
233 (4) 
224 (4) 
200 (3) 
149 (2) 
149 (2) 
148 (2) 
126 (2) 
112 (2) 
106 (2) 
85 (1) 
84 (1) 
82 (1) 
71 (1) 
63 (1) 
I Excludes codes beginning with X and Y (causes of event), U (special-purpose 
codes), and R (symptoms, signs, and laboratory findings). 
Table 9. First-listed diagnoses where opioid poisoning was given as a secondary 
condition (all where proportion o/total > 1%/ 
ICD-10 
code 
T391 
T424 
F329 
T405 
T432 
T430 
T393 
F100 
F432 
F430 
T510 
T435 
T450 
T426 
F191 
Description 
Poisoning: 4-Aminophenol derivatives (acetaminophen) 
Poisoning: Benzodiazepines 
Depressive episode, unspecified 
Poisoning: Cocaine 
Poisoning: Other and unspecified antidepressants 
Poisoning: Tricyclic and tetracyclic antidepressants 
Poisoning: Other NSAIDs (excludes ASA, acetaminophen) 
Acute intoxication 
Adjustment disorders 
Acute stress reaction 
Toxic effects of ethanol 
Poisoning: Other and unspecified anti psychotics and neuroleptics 
Poisoning: Antiallergy and antiemetic drugs 
Poisoning: Other antiepileptics and sedative-hypnotic drugs 
Mental and behavioural disorders due to multiple drug use and use 
of other psychoactive substances 
Occurrenc 
es (%) 
396 (17) 
324 (14) 
132 (6) 
96 (4) 
61 (3) 
58 (3) 
38 (2) 
35 (2) 
34 (1) 
30 (1) 
29 (1) 
26 (1) 
25 (1) 
23 (1) 
22 (1) 
1 Excludes codes beginning with X and Y (causes of event), U (special-purpose 
codes), and R (symptoms, signs, and laboratory findings). 
Regression results 
Models including time only revealed that trends are highly significant for all event 
types (table 10). Incidence rate ratios (per year) were 1.11 (95%CI=1.08 to 1.15) for 
the total count of events, 1.07 (95%CI=I.03 to 1.10) for incidents of self-harm, 1.13 
(95%CI=1.08 to 1.18) for events of undetermined or other causes, and 1.15 (1.11 to 
1.20) for accidental poisonings. Accidental poisonings and poisonings of 
undetermined intent thus grew at approximately twice the rate of incidents of self-
harm. 
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Table 10. Testsfor trends for events by type: Incidence rate ratios for year from 
time-only Poisson regression models. 
Total 
Accidental 
Self-harm 
Undetermined, other 
IRR 
1.11 
1.15 
1.07 
1.13 
IRR L95% 
1.08 
1.11 
1.03 
1.08 
IRR U95% 
1.15 
1.20 
1.10 
1.18 
p 
<0.001 
<0.001 
<0.001 
<0.001 
Models including sex only revealed no difference between the sexes (IRR=1.02, 
p=0.57) in total event rates. This obscures differences in types of events, however, 
with self-harm modestly but significantly more common among women and 
undetermined/other events more common among men (table 11). Differences among 
individual age/sex groups, which were compared to men aged 25 to 49, were 
generally highly significant (table 12). All three outcomes were least common among 
children under 15, while accidental or undetermined poisonings were most common 
among men aged 25 to 49 (the reference category) and incidents of deliberate self-
harm were equally common in this group and among women between 15 and 49. All 
outcomes became somewhat less common in later life, self-harm particularly so: IRRs 
among men and women aged 65 or older were 0.17 and 0.14, respectively. Results of 
models including demographic categories, rurality, income, and non-opioid substance 
poisonings are presented in tables 13a, 13b, and 13c. 
Table 11. Tests for gender differences by event type: Incidence rate ratios for gender 
from gender-only negative binomial regression models (females relative to males). 
IRR IRR L95% IRR U95% P 
Total 1.02 0.96 1.08 0.57 
Accidental 0.97 0.89 1.07 0.59 
Self-harm 1.17 1.07 1.27 <0.001 
Undetermined, multiple, other 0.83 0.74 0.92 0.001 
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Table 12. Tests for differences among age/sex groups (model 2): Incidence rate 
ratios from age/sex-only negative binomial regression models (reference group = 
males 25 to 492-
Accidental, undetermined, 
Total or other Self-harm 
IRR {95% CI} ~ IRR (95% CI) ~ IRR {95% CI} P 
Males 
o to 14 0.14 (0.12 - 0.18) <0.001 0.25 (0.21 - 0.31) <0.001 0.01 (0.01 - 0.03) <0.001 
" 15 to 
24 0.62 (0.54 - 0.71) <0.001 0.61 (0.51 - 0.72) <0.001 0.62 (0.52 - 0.75) <0.001 
25 to 
49 (Reference) (Reference) (Reference) 
50 to 
64 0.50 (0.45 - 0.57) <0.001 0.54 (0.47 - 0.63) <0.001 0.46 (0.39 - 0.55) <0.001 
65+ 0.39 (0.34 - 0.46) <0.001 0.59 (0.49 - 0.7) <0.001 0.17 (0.12 - 0.25) <0.001 
Females 
o to 14 0.15 (0.13 - 0.18) <0.001 0.20 (0.16 - 0.25) <0.001 0.09 (0.07 - 0.13) <0.001 
15 to 
24 0.84 (0.75 - 0.94) 0.003 0.66 (0.56 - 0.77) <0.001 1.07 (0.92 - 1.24) 0.41 
25 to 
49 0.86 (0.79 - 0.93) <0.001 0.71 (0.64 - 0.79) <0.001 1.03 (0.92 -1.15) 0.61 
50 to 
64 0.59 (0.52 - 0.67) <0.001 0.63 (0.55 - 0.73) <0.001 0.54 (0.45 - 0.65) <0.001 
65+ 0.43 {0.38 - 0.49} <0.001 0.69 {0.6 - 0.8} <0.001 0.14 {0.1 - 0.19} <0.001 
As noted, examination of the bivariate association between availability of specialist 
care and opioid poisoning (figure 2) indicated a generally inverse relationship. A 
small number of data points were at high levels of both variables, implying a possible 
U -shaped association. Results from full models are presented in tables 14a, 14b, and 
14c. 
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Table 13a. Results from negative binomial regression model 3 predicting total opioid 
poisoning events. 
IRR 12 IRR L95% IRR U95% 
Males 
o to 14 0.16 -18.84 <0.001 0.13 0.19 
15 to 24 0.65 -6.45 <0.001 0.57 0.74 
25 to 49 Reference 
50 to 64 0.53 -10.33 <0.001 0.47 0.60 
65+ 0.40 -11.90 <0.001 0.34 0.47 
Females 
o to 14 0.16 -19.17 <0.001 0.14 0.20 
15 to 24 0.88 -2.27 0.02 0.78 0.98 
25 to 49 0.89 -2.75 0.01 0.82 0.97 
50 to 64 0.62 -7.93 <0.001 0.55 0.70 
65+ 0.44 -12.82 <0.001 0.39 0.50 
Non-opioid drug overdoses 1.33 11.81 <0.001 1.27 1.40 
Rural 1.11 1.45 0.15 0.96 1.28 
Family median income (per 
$10,000) 0.89 -7.09 <0.001 0.86 0.92 
Figure 2. Rates of contacts for opioid poisoning due to accidental, undetermined, or 
other causes by specialist availabililty (dots sized by population represented). 
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This association was borne out by results from the full models; for all three outcomes, 
two polynomial terms proved optimal. Figure 3 shows the predicted rate of poisoning 
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events of each type across levels of specialist availability with other variables held to 
their means. In all three models, this relationship is non-linear, with a decrease in 
poisonings with greater availability of specialist care at low levels of the latter 
variable transitioning to an increase at higher concentrations of specialists. The 
magnitude of the association was stronger for incidents of self-harm apd total 
incidents than for accidental, undetermined, and other events. All three functions 
reach minima between 150 and 200 specialist physicians per 100,000 population. 
Figure 3. Predicted rates of opioid poisonings across levels, of specialist availability 
from full negative binomial regression models. 
16 
14 
~ 120---
o 
.... 
! 10 
.l!l 
I: 
~ 8 
CI .... _---- .. _-._--
.!: 6 
I: 
o 
Ul 
'0 4 
Il. 
2 
-----
---
---
... -. .... _,-
---
---
-----------
---..... 
---
.... " 
/ 
/ 
/ 
I 
I , 
__ "L __ 
~~~ 
... '-
/' 
o+-------~----~------~------~----__, 
o 50 100 150 200 250 
Specialist physicians per 100k 
- - - - - -Accidental, 
undetermined, 
other 
- - - Self-harm 
-Total 
Median family income was inversely and significantly associated with rates of opioid 
poisoning in all models, while rurality was non-significant in all cases. Effects for 
rates of ED use for illicit drug or alcohol poisoning, which, as noted, was modeled 
using a square root transformation, were significant and positive for all three 
outcomes. Predicted rates for all outcomes across levels of this variable with all 
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others held to their means are shown in figure 4. The middle 90% of the distribution 
of FSA-level poisoning rates are included in this figure. 
Interactions between the specialist care variables and rurality, non-opioid drug 
overdose rate, and median family income were explored and proved tc? be non-
significant in all models. 
Table 13b. Results from negative binomial regression model 3 predicting accidental, 
undetermined, or other events. 
IRR ~ !RR L95% IRR U95% 
Males 
o to 14 0.27 -12.49 <0.001 0.22 0.33 
15 to 24 0.63 -5.31 <0.001 0.54 0.75 
25 to 49 Reference 
50 to 64 0.57 -7.37 <0.001 0.49 0.66 
65+ 0.59 -5.98 <0.001 0.50 0.70 
Females 
o to 14 0.21 -14.11 <0.001 0.17 0.26 
15 to 24 0.68 -4.83 <0.001 0.58 0.80 
25 to 49 0.74 -5.56 <0.001 0.66 0.82 
50 to 64 0.66 -5.58 <0.001 0.57 0.77 
65+ 0.70 -5.04 <0.001 0.60 0.80 
Non-opioid drug overdoses 1.33 11.22 <0.001 1.27 1.40 
Rural 1.06 0.76 0.45 0.91 1.25 
Family median income (per 
$10,000) 0.88 -6.97 <0.001 0.85 0.91 
Table 13c. Results from negative binomial regression model 3 predicting events due 
to intentional self-harm. 
IRR ~ IRR L95% IRR U95% 
Males 
o to 14 0.01 -10.44 <0.001 0.01 0.03 
15 to 24 0.65 -4.78 <0.001 0.54 0.77 
25 to 49 Reference 
50 to 64 0.48 -8.29 <0.001 0.41 0.57 
65+ 0.17 -9.95 <0.001 0.12 0.25 
Females 
o to 14 0.10 -13.18 <0.001 0.07 0.14 
15 to 24 1.11 1.34 0.18 0.95 1.28 
25 to 49 1.07 1.19 0.23 0.96 1.19 
50 to 64 0.57 -6.44 <0.001 0.48 0.67 
65+ 0.14 -12.71 <0.001 0.10 0.19 
Non-opioid drug overdoses 1.35 9.82 <0.001 1.27 1.44 
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Rural 
Family median income (per 
$10,000) 
1.19 
0.89 
1.97 0.05 
-4.91 . <0.001 
53 
1.00 1.42 
0.85 0.93 
" 
Figure 4. Predicted rates of opioid poisonings across levels of illicit drug or alcohol 
poisonings from full negative binomial regression models. 
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Table 14a. Results of full negative binomial regression model 4 predicting total 
number of events across study l!.eriod. 
IRR ~ IRR L95% IRR U95% 
Specialists per 1000a 0.80 -6.25 <0.001 0.74 0.86 
Specialists per 1000b 1.31 6.89 <0.001 1.21 1.42 
Nonspecialists per 100k 1.00 0.01 0.995 0.996 1.004 
Males 
o to 14 0.16 -18.91 <0.001 0.13 0.19 
15 to 24 0.64 -6.60 <0.001 0.56 0.73 
25 to 49 Reference 
50 to 64 0.53 -10.54 <0.001 0.47 0.59 
65+ 0.40 -11.95 <0.001 0.34 0.46 
Females 
o to 14 0.16 -19.28 <0.001 0.14 0.20 
15 to 24 0.87 -2.33 0.02 0.78 0.98 
25 to 49 0.89 -2.81 0.01 0.82 0.97 
50 to 64 0.62 -7.98 <0.001 0.55 0.70 
65+ 0.44 -12.96 <0.001 0.38 0.49 
Non-opioid drug overdoses 1.31 10.63 <0.001 1.25 1.38 
Rural 0.99 -0.18 0.86 0.85 1.14 
Family median income (per 
$10,000} 0.87 -8.35 <0.001 0.84 0.90 
a (Availabilityll 00)3 
b (A vailabilityll 00)3 -In(A vailability/l 00) 
Table 14b. Results offull negative binomial regression model 4 predicting total 
number of accidental, undetermined, or other events across study period. 
IRR T P IRR L95% IRR U95% 
Specialists per 1000a 
Specialists per 1000b 
Nonspecialists per 100k 
0.87 -3.25 0.001 0.80 0.95 
1.18 3.35 0.001 1.07 1.30 
1.00 -0.19 0.85 0.99 1.004 
Males 
o to 14 
15 to 24 
25 to 49 
50 to 64 
65+ 
Females 
o to 14 
15 to 24 
0.27 -12.54 
0.63 -5.40 
0.57 -7.42 
0.59 -6.03 
0.21 -14.21 
0.68 -4.83 
25 to 49 0.74 -5.53 
50 to 64 0.66 -5.62 
65+ 0.69 -5.12 
Non-opioid drug overdoses 1.31 10.24 
Rural 0.98 -0.29 
Family median income (per 
$10,000} 0.87 -7.59 
a (A vailabilityll 00)3 
b (AvailabilityIl00)3 -In(AvailabilityIlOO) 
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<0.001 0.22 
<0.001 0.53 
Reference 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
0.77 
<0.001 
0.49 
0.50 
0.17 
0.58 
0.66 
0.57 
0.60 
1.24 
0.82 
0.83 
0.33 
0.75 
0.66 
0.70 
0.26 
0.80 
0.82 
0.76 
0.80 
1.38 
1.15 
0.90 
Table 14c. Results offoll negative binomial regression model 4 predicting total 
number of self-harm events across studJl..p"eriod 
IRR t P IRR L95% IRR U95% 
Specialists per 1000a 0.41 -7.50 <0.001 0.33 0.52 
Specialists per 1000b 1.46 6.91 <0.001 1.31 1.63 
Nonspecialists per 100k 1.00 0.46 0.65 0.997 1.01 
Males 
o to 14 0.01 -10.46 <0.001 0.01 0.03 
15 to 24 0.64 -4.93 <0.001 0.53 0.76 
25 to 49 Reference 
50 to 64 0.47 -8.58 <0.001 0.40 0.56 
65+ 0.17 -10.02 <0.001 0.12 0.24 
Females 
o to 14 0.10 -13.26 <0.001 0.07 0.14 
15 to 24 1.10 1.24 0.22 0.95 1.27 
25 to 49 1.06 1.04 0.30 0.95 1.18 4 
50 to 64 0.56 -6.57 <0.001 0.47 0.66 
65+ 0.14 -12.79 <0.001 0.10 0.19 
Non-opioid drug overdoses 1.33 8.72 <0.001 1.25 1.42 
Rural 1.01 0.13 0.90 0.85 1.21 
Family median income (per 
$10,000) 0.88 -6.19 <0.001 0.84 0.91 
a (Availability/lOoi 
b (A vailabilityll 00)3 
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Discussion 
Opioids are medically necessary, and their increased use has arisen in part due to 
well-intentioned efforts to promote their use for the relief of severe pain. A large 
body of evidence now demonstrates, however, that increases in general availability 
have been accompanied by increases in non-medical use. Existing wqrk from large-
scale studies in the United States has shown that fatal and non-fatal overdose from 
prescription opioid use has become a significant public health issue over the past 
twenty years (Paulozzi, 2006; Dasgupta, 2006). Similarly, research in Canada has 
found that non-medical use of prescription opioids is now reported by substantial 
proportions of people with substance-related problems (e.g., Fischer et aI., 2005) and 
is now not uncommon in the general population (e.g., Adlaf & Paglia-Boak, 2007). 
Canadian population surveys have only recently begun to inquire about use of 
prescription opioids, which makes judgements about recent changes difficult. The 
fact that this information is now collected at all, however, is symptomatic of the 
increasing concern surrounding this issue. 
Epidemiology of opioid poisoning in Ontario 
Perhaps the most robust finding in the present analysis is the substantial increases in 
incidence and event rates over time: Year over year, all categories of events increased 
substantially and, with one minor exception, monotonically, with a total increase in 
rates for all included poisonings of approximately 40% over a 4 year period. This 
corresponds to an annualized increase of 11.8%. Although the baseline rate, at 
approximately 1 event per 1000 people per year, is relatively low, such a change is 
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nevertheless remarkable. While it would be a mistake to extrapolate from the end of 
the study period to the present or beyond, it is also clear that the level of poisonings 
had not stabilized by 2005. 
Risk and public health burden 
In 2005, there were 1056 incidents potentially arising from intentional misuse of 
prescription opioids, and a further 760 events due to deliberate self-harm. By the end 
of the study period, there were approximately l.5 events per 10,000 people per year 
in Ontario. By way of comparison, there were approximately 200 total ED contacts 
per 1000 people in 2000 (Chan et al., 2001). Overdose on prescription opioids thus 
appears to account for very approximately 0.075% of ED visits in the province. 
Depending on the severity of the poisoning cases, however - on which there is little 
available information - the clinical burden may be higher than this figure suggests. 
Across the study period, poisonings involving opioid analgesics outnumbered those 
due to all illicit drugs combined. There were 5275 incidents involving cocaine, 
heroin, opium, cannabis, or hallucinogens, and a further 1956 due to "stimulants with 
abuse potential" (a category including prescription stimulants, methamphetamine, and 
MDMA). Although incidents of self-harm may be partly responsible for the 
preponderance of prescription opioids in ED data, accidental overdoses alone make 
up a large proportion of all poisonings. These results also bear out existing studies 
that have shown a displacement of heroin by prescription opioids. Over the study 
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period, there were 6283 incidents of opioid analgesic overdose and 236 of heroin 
poisoning, a ratio of approximately 27 to 1. 
A very rough assessment of risk relative to exposure is made possible by comparing 
the volume of drugs dispensed to the number of poisoning events recorded. In 2005, 
Ontario retail pharmacies filled 5.3 million prescriptions of opioid analgesics and 
dispensed a total of 387.7 million doses of these medications. This implies a rate of 
approximately 1 ED contact per 62,000 doses, or per 840 prescriptions. This 
calculation necessarily excludes cases where no ED contact was made or where the 
overdose was identified as a 'complication of care', however, and also does not take 
into account use of over the counter codeine preparations or of certain opioids that 
appear to be uncommonly prescribed in Ontario, such as propoxyphene. Codeine and 
hydrocodone are included on grounds that, although these "weak" opioids are less 
toxic in overdose than stronger ones, their use has nonetheless been linked to ED 
contacts for poisoning at rates not substantially lower than those for other drugs 
(Dasgupta et aI., 2006). 
Involvement of other substances 
Poisoning due to other medications and drugs was noted in 35% of incidents. 
Involvement of other substances is the norm in cases of fatal overdose, however. 
There are two likely explanations for this discrepancy. The first is that the detection 
ratio in ED settings may be considerably lower than in coroners' investigations: The 
latter may involve more thorough toxicological work, and investigators have 
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essentially unlimited access to the individual as well as, presumably, significantly less 
time pressure than is usual in emergency care. Moreover, it is possible that 
involvement of other drugs may sometimes go unrecorded in ED settings, or, at least, 
fail to be entered into administrative databases. The other probable explanation is 
simply that, as noted, certain drug combinations significantly increase, the lethality of 
overdoses involving opioids. Such overdoses are thus likely to be overrepresented, 
perhaps dramatically so, in studies of fatalities, relative to the total set of overdoses 
occurnng. 
The most common other substances involved are benzodiazepines and 
acetaminophen. This is unsurprising. As noted, benzodiazepines are known to be a 
popular choice for combination with opioids among recreational users and have 
independent respiratory depressant effects. They are thus more likely to be used with 
opioids than other drugs, and this combination is, moreover, more likely to result in 
overdose necessitating emergency care. They also share common sources with 
prescription opioids: Physician prescriptions, pharmacies, and individuals who 
illicitly distribute prescription medications. People with access to prescription 
opioids may thus also have access to benzodiazepines. 
Acetaminophen, by contrast, is not used recreationally. Although it is conceivable 
that it might be combined deliberately with opioids in some incidents of self-harm, 
the likeliest explanation for its appearance in ED records is that it is very frequently 
compounded with opioids in prescription medications. Acetaminophen is particularly 
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common in preparations including codeine (e.g., Tylenol 3) and oxycodone (e.g., 
Percocet), and its toxic effects may be risked, possibly unawares, by individuals 
taking these medications for the opioids they contain. The immediate effects of 
acetaminophen poisoning - typically nausea and vomiting - may also help decide 
overdose victims or others in favour of seeking emergency care, despi~e the fact that 
the much more serious hepatotoxic effects of the drug do not manifest for a period of 
two or three days (by which time overdoses on most opioids would have long 
resolved). 
The fact that alcohol was recorded in only 3% of events probably does not reflect its 
actual level of involvement. The ICD-l 0 code recorded in these cases, "toxic effects 
of ethanol", may have been omitted in cases where alcohol toxicity was not judged to 
be clinically serious. Alcohol, however, may increase the risk of overdose, both 
directly, via its respiratory depressant effects, and indirectly via its impact on the 
absorption of some opioid preparations. It may be that ICD-l 0 poisoning codes are 
seldom used to indicate such effects. 
Other recreational drugs represented included cocaine, which is not uncommonly 
mixed with opioids by users, and cannabis. The use of a poisoning code with 
cannabis is slightly curious given the limited toxicity of this drug. In all cases, 
however, it seems likely that the proportion of cases in which other substances were 
involved was somewhat higher than these data suggest, since the ICD-l 0 codes used 
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indicate "poisoning", and codes indicating mere intoxication were very rarely present 
in these data. 
The third most common set of co-occurring substances were antidepressant and 
antipsychotic medications. Given the limited recreational potential of,almost all 
drugs in these classes, these seem likeliest to occur in the context of intentional self-
harm; access to these medications, for which there is no known, substantial illicit 
market, is itself likely to indicate the presence of psychiatric disorders that place 
sufferers at an increased risk of suicide. The relative prominence oftricyclic and 
tetracyclic antidepressants, which occur at half the rate of "other and unspecified 
antidepressants" despite being much less widely prescribed (Hemels et aI., 2002), 
presumably reflects the much greater toxicity of these substances in overdose (e.g., 
Barbey & Roose, 1998). 
Demographic differences 
There were no significant gender differences in total rates of overdose on prescription 
opioids. Events of undetermined intent were more common among men, however, 
while self-harm was more common among women. The finding of gender parity in 
the overall rate is of some interest, since rates of substance misuse, abuse, dependence 
(e.g., Kessler et aI., 2005), and overdose (e.g., Hall et aI., 2008) are typically higher 
among men. This is not always the case in studies on opioids, however, which is 
suggestive of an intriguing gender difference in substance preference - particularly 
since the relative similarity of rates extends not only to prescription medications 
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(where there may be differences in access due to, for example, higher rates of 
physician contact by women), but also to heroin .. 
Age differences were substantial and highly significant. Total event rates were low 
among children under 15, and the majority of such events were code(as accidents. 
Self-harm was uncommon among people 65 or older, while those event types 
considered here as potentially due to intentional, non-medical use (accidents and 
events of undetermined intent) peaked among people aged 15 to 49. Among men, 
rates were noticeably higher among those 25 to 49 than among younger adults, while 
in women rates were very similar in these two age groups. The mean age of people 
presenting was somewhat younger among women, and this remained the case after 
incidents of self-harm were excluded. 
Prescription opioids and self-harm 
The study period saw large increases in accidental poisonings, but also substantial, 
though smaller, increases in the number of individuals using these medications in 
incidents of deliberate self-harm. Although most research has focused on 
"recreational" use and on overdoses presumed to result from such use, it therefore 
appears that increased availability of prescription opioids has also been associated 
with increased use of these drugs in suicide attempts or suicidal gestures. This is a 
comparatively little-studied phenomenon, perhaps in part because it is unclear 
whether access to opioids makes suicide attempts or other acts of self-harm more 
likely, or whether they simply displace other (possibly equally or more lethal) means. 
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Variation in the availability of lethal substances has, however, been linked to 
differences in rates of completed suicide: Easy access to pesticides, for example, is 
thought to underlie urban/rural differences in suicide mortality in many parts of the 
world (Gunnell et aI., 2007). Although opioids are considerably less lethal in 
overdose, their availability may similarly influence rates of completeq suicide or 
related harms, even in the absence of any change in rates of suicide attempt. In any 
case, iflevels of ED contacts are a reasonable guide, self-harm comprises a 
considerable part of the clinical, and perhaps public health, burden of opioid misuse. 
Existing investigations of opioid overdose have also generally ignored events arising 
in the course of care. Although such incidents could not be included in the present 
analysis, this is another substantial source of opioid-related harm that should be part 
of evaluations of the risks and benefits of these medications. 
Opioid poisoning and availability of specialist medical care 
The second part of the analysis presented considers the potential association between 
availability of specialist care, as measured by the number of specialist physicians per 
unit population in the local census division, and the rate of ED contacts for 
prescription opioid poisoning. As noted, such an association suggests itself because 
of the ways in which opioids are obtained. Sources of opioid analgesics are local, 
unlike those of most illicit drugs, and largely come, ultimately, from physician 
prescriptions. As there is some evidence that specialist providers are more likely to 
appropriately prescribe and manage these medications, their misuse may be more 
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common or more serious in areas where most care is provided by general 
practitioners. 
Availability of specialist care was significantly associated with all outcomes. These 
• 
associations were, however, non-linear. In all cases, the expected invt?rse association, 
such that a lower concentration of specialists was linked to higher event rates, was 
found in the lower parts of the distribution. After reaching minima at approximately 
160 physicians per 100,000 population in all models, however, the predicted values 
begin to increase. The initial decrease can be interpreted as the expected effect, 
resulting from some combination of the proposed mechanisms: Poorer management 
of opioids; more inappropriate prescription of opioids; and an increased need for 
strong analgesics for conditions that might otherwise have been prevented or 
ameliorated. 
The increase in events at higher concentrations of specialist providers is supported by 
the bivariate association (figure 2), which suggested such a relationship. One 
interesting interpretation of this finding is that greater availability of care leads to a 
greater general availability of opioids. Even if prescriptions written in specialist-rich 
areas are appropriate and medications well-managed, a much greater general 
availability of opioids may lead to more misuse. Although there are limited Canadian 
data in this area, work in the United States has uncovered large variations between 
states in the levels of opioid prescription, and, importantly, found an independent 
association between total opioids prescribed and the number of practicing surgeons 
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per unit population (Curtis et ai., 2006). These geographical differences may be 
analogous to the changes noted over time in the United States (Paulozzi & Ryan, 
2006; Dasgupta et aI., 2006), where levels of prescriptions and rates of overdoses 
increased in step. Questions that follow concern the amounts of opioids prescribed in 
different areas within Ontario, whether they reflect overuse in some, l!nder-use in 
others, or some combination of both, and whether some increase in non-medical use 
and in overdose is unavoidable when opioids are provided to all those who need 
them. 
An alternative explanation, however, concerns unmeasured (and potentially 
unmeasurable) geographical differences. Toronto lies above the general trend of the 
first part of the curve of predicted values and includes some 20% of the provincial 
population. As a large urban area, it also has a high concentration of specialists, a 
high concentration of substance dependence treatment facilities, and some areas of 
significant poverty or social disorganization. A reanalysis of the data without 
Toronto, however, did not substantially alter the effect. It remains true, however, that 
the higher part of the distribution of the specialist availability variable includes 
relatively few regions, and that the improvement in model fit from the addition of a 
second transformation of the availability variable will have resulted from improved fit 
at these points. While intriguing, therefore, this result should be treated with caution. 
Analysis of data at a finer level of resolution might clarify the association. 
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The relationship between specialist care and poisoning events was markedly stronger 
for incidents of self-harm than for events of accidental or undetermined intent. While 
the latter outcome varies by a factor of approximately 1.5 across levels of specialist 
availability, self-harm varies by a factor of3. This finding is somewhat unexpected. 
It is not entirely surprising that use of opioids in attempts at self-harm, should follow a 
similar pattern to that of total poisonings, as this is another unintended use that might 
be expected to become more common where opioids are more readily available. 
What is surprising, however, is the relative strength of this association. One 
explanation concerns possible variations in overall background rates of self-harm. 
Specialist physicians tend to be concentrated in large cities (table 2), and these cities 
are also centres of psychiatric treatment. Evidence on urban/rural differences in 
completed suicide is decidedly mixed, however, with at least some North American 
studies (e.g., Singh & Siapush, 2002) reporting elevated incidence in rural areas. 
There are limited data on urban/rural differences in suicide attempts in Canada. 
Results from the 2002 Canadian Community Health Survey - cycle 1.2 show, 
however, that self-reported past-year suicide attempt is less common in Toronto 
(0.27%) than in the province as a whole (0.59%) and, notably, is most common in 
northern Ontario (1.25%), which has a very low levels of specialist availability 
(unpublished data). Bringing more detailed data to bear on this question would likely 
prove valuable. 
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Model covariates 
Though included in all models as a conceptually important control variable, the 
availability of general medical care did not have a significant, independent 
association with any of the outcomes examined. This may be due in part to relatively 
limited variability in this indicator: The coefficient of variation at the~ensus division 
level was 26%, as compared to 87% for specialist availability. 
Most demographic variables were highly significant in all models, which indicates 
that the results obtained in the demographics-only model are not accounted for by 
differences in other factors. Rurality was non-significant in all models, and was also 
not significantly associated with poisoning rates at the bivariate level. This contrasts 
with work in parts of the United States, which has shown that overdose on 
prescription opioids is now somewhat more common in rural than in urban areas 
(CDC, 2005). It is unclear what underlies this difference. It is also not obvious, 
however, that such a difference should be expected to be universal; although rural 
areas throughout both countries have some potential risk factors in common, 
including low availability of medical care and often lower economic status, there are 
also substantial differences. Although there are regions of great poverty and 
deprivation in Ontario, particularly in remote areas, studies in the United States have 
included larger and more populous areas of rural poverty than exist in the province. 
Median household income was inversely associated with overdose rates. Although 
interpretation of this effect is not straightforward due to the scale of the original 
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variable, the difference between 1 SD below the mean and 1 SD above the mean on 
this indicator corresponds to a difference in the total event rate of approximately 70% 
when other variables are held to their means. Income, wealth, education, and other 
measures of socioeconomic status are generally associated with better health at both 
the individual and regional levels. 
The background rate of ED use for poisonings due to use of illicit substances or 
alcohol was highly significant in all models. The effect was fairly substantial; an 
increase in the rate of illicit drug or alcohol poisoning from 8 to 16 per 100,000 
(corresponding to approximately -1 SD to + 1 SD at the FSA level), for example, 
results in an increase in the rate of total opioid poisonings of 37% (from 8.6 to 11.8 
per 100,000) when other variables are held to their means. This agrees with recent 
Canadian studies (e.g., Fischer et aI., 2006) of people with a history of substance 
dependence, which have shown that use of prescription opioids is now very common 
in this population. More broadly, this association shows that prescription opioid 
misuse covaries with misuse of other substances. Along with the obvious similarities 
of the two phenomena, this suggests that they share common underlying causes. 
Although media reports, for example, sometimes suggest that most cases of opioid 
"addiction" are iatrogenic and represent a wholly different phenomenon than illicit 
drug dependence, the present results add to existing evidence indicating that 
prescription opioids, alcohol, and illicit drugs share a common appeal and a common 
demographic. 
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Implications 
Results demonstrate that rates of poisoning from prescription opioid use increased 
substantially over the study period, and that the rate of this increase was relatively 
steady. Although rates since the end ofthe study period are unknown, it is clear that 
ongoing monitoring of this issue is crucial. Unlike the United States,»,hich operates 
an ED-based system that centralizes records of drug-related harms (the Drug Abuse 
Warning Network), Canada does not systematically monitor such events. Such a 
system would have important advantages. In addition to rapid identification of 
emerging clusters of drug overdose (of the kind that might appear as the result of 
increases in illicit drug purity or availability), tracking of ED contacts would make it 
possible to react more expeditiously to broader trends in poisonings or other events 
(Kleine et aI., 2007). 
What the policy reaction to increased rates of opioid overdose should be, however, is 
not obvious. Opioids are a class of drugs which, like sedative/hypnotics such as the 
benzodiazepines and stimulants such as methylphenidate, have important medical 
uses but also significant potential for misuse. Significant efforts have been made to 
ensure access to opioids, and the expansion of their use may represent an important 
advance in the relief of pain and the treatment of opioid dependence. The risk of 
overdose per unit consumed is also relatively small. Finally, it is also not always 
clear what overall impact changes in the use of individual substances or classes of 
substance have, from a public health perspective, on the level of substance-related 
harms in general. For existing users, some substances are highly substitutable, as in 
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the case of heroin and the opioid analgesics themselves. The OSDUHS survey has 
also found decreases, often sharp, in the use of various substances among Ontario 
adolescents over the past 10 years. It is intriguing that these declines have coincided 
with a period of increased availability and misuse of the opioid analgesics. 
These considerations make policy approaches to the increasing misuse of opioids 
particularly fraught. Broad attempts to limit their use may negatively affect people 
for whom they are necessary and appropriate medications. Even efforts to improve 
oversight of prescribers might discourage physicians from providing opioids in cases 
where they would be appropriate. One obvious approach is to improve medical 
education with respect to the management of pain; as noted, many general 
practitioners do not feel adequately prepared for the management of patients requiring 
strong opioids (Hutchinson et al., 2006). Another possibility concerns the monitoring 
of prescription patterns. Such data have been put to use in pharmaceutical 
companies' marketing efforts in the United States (Van Zee, 2009). A better use 
might involve the identification of opportunities to intervene - educationally rather 
than punitively, in most cases - in situations where physicians appear to be 
prescribing excessively or indiscriminately. It is not clear, however, that identifying 
the small proportion of physicians with obviously problematic prescribing practices 
would have an enormous impact on opioid availability, and such monitoring might be 
unpopular with physicians in any case. 
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A further possibility concerns the use of "opioid contracts", which are agreements 
(often not actually identified as "contracts") betWeen providers and patients that 
explicitly set out the conditions for treatment with opioid analgesics. These almost 
invariably include prohibitions on selling or distributing medication, using excessive 
amounts, and seeking other sources of prescriptions (Fishman, 1999)., Such 
documents are sometimes intended to be principally educational (Gitlin, 1999), 
however, and it is not clear how effective they are in deterring these behaviours. In 
any case, physicians, medical professional organizations, and medical educators 
probably have the greatest ability to reduce or ameliorate the consequences of opioid 
misuse without adversely affecting care. 
The future of opioid prescription misuse is unclear, other than the obvious fact that it 
can be expected to persist. In the modem era, misuse of opioids has waxed and 
waned with variations in regulation, availability, and with cultural shifts generally. 
More novel substances such as synthetic sedative-hypnotics and stimulants have had 
similar histories. Illicit use of some specific drugs and classes of drugs, such as 
methaqualone and the barbiturates, has almost ceased, but only because they have 
been withdrawn from sale or displaced by other medications. Use of medical opioids 
cannot be eliminated, and it remains to be seen how effective policy approaches will 
be in reducing levels of misuse and related consequences, such as overdose. 
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Limitations 
The analysis presented has several important limitations. First, as noted, the analysis 
is an ecological one: Data are aggregated to regions, but inferences are drawn about 
outcomes for individuals. Although the large number of areas analyzed may have 
mitigated this problem, this study remains vulnerable in principle to ili.e difficulties 
common to ecological analyses. 
The nature of the geographical data available was also unfortunate, in that the primary 
units of analysis, FSAs, did not nest within the larger regions ( census divisions) for 
which physician availability data were obtainable. This necessitated the estimation of 
values for a substantial proportion of data by using a weighted average of regional 
values. Although this approach arguably does not necessarily result in less accurate 
results than assigning census division values to those FSAs that fully nest within 
them, it highlights the somewhat coarse and approximate nature of the exposure 
measure. One assumption that may be problematic is that census district level 
indicators accurately reflect availability of services. Although it is likely that census 
divisions are sufficiently large that this is not a critical issue, these census boundaries 
are partly arbitrary, and use of care in an adjacent region may be common. This may 
be a particular issue in the case of areas bordering on Toronto or Ottawa, which have 
very high concentrations of specialists; apparent relative scarcities in the suburbs of 
these cities may actually reflect the ease of travel to care in a nearby city. Any bias of 
this type should, however, be conservative. 
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An equally important issue concerns the possibility of confounding by unmeasured 
variables. This analysis involves geographical differences, and attempts to take into 
account population differences in age and sex distributions, income, illicit drug and 
alcohol poisoning, rurality, and availability of general practitioners. These are clearly 
not the only potential determinants of prescription opioid poisoning rates, however. 
" 
Like other behaviours or health outcomes, much spatial variation in rates of 
problematic substance use is not easily accounted for by measured variables. Some 
variation may be simply "cultural" and nearly unmeasurable. One potential difficulty 
is that the number of recorded contacts reflects not only of the background incidence 
of opioid overdose, but also the likelihood that such an event will result in an ED 
visit. In the case of relatively mild poisonings, such differences might be substantial, 
being driven in part, perhaps, by proximity to emergency care. Proximity to an ED is 
itself likely to be correlated with specialist availability. This association may result in 
a conservative bias, however, as it suggests that people in areas with low availability 
of specialists may also be less likely to visit an ED, as a result of poorer access. The 
inclusion of an indicator of ED use for other drug poisonings is very important with 
respect to this type of unmeasured geographical difference, as this is another outcome 
that can be expected to vary with such things as availability of EDs and propensity to 
seek care. 
Although this project is concerned with poisoning from prescription opioids, it is not 
always possible to distinguish prescription from illicit drugs. Since heroin is 
metabolized to morphine in the body, determination of the substance responsible for 
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overdose will sometimes be impossible, or will rely on patient information, the 
detection of adulterants commonly found in heroin, or other indications that lead to a 
strong presumption of heroin use. Records are heroin use are sparse in these data, 
however, with a total of 236 cases recorded across the study period. Since it is likely 
that clinicians would have information sufficient to distinguish betwe~n heroin and 
prescription opioid use in many cases, it seems unlikely that confusion of this kind 
had a significant impact on the results. This study also includes all contacts for which 
opioid poisoning is listed as a diagnosis. It therefore includes cases in which other 
drugs or other conditions contribute to the admission. 
It is also important to note that the data in this study reflect only ED visits for opioid 
poisoning. They do not include incidents of overdose for which no help was sought, 
which were dealt with by physicians in other contexts (e.g., in institutional settings), 
or fatal poisonings for which no ED contact occurred. Incidences and numbers of 
events presented here therefore represent a subset of all those poisonings that 
occurred in the province within the study period. 
The available data on ED visits are also limited in several ways. leD codes for 
diagnosis do not, in general, make it possible to distinguish different prescription 
opioids. A more serious limitation is the nature of the information available on types 
of events. Although I have followed existing work in including 'accidental' 
overdoses and 'events of undetermined intent' in the final model, it is important to 
note that not all of these incidents will have been the result of deliberate misuse of 
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opioids for recreational purposes. Instead, these two broad categories include several 
other possibilities, notably attempts at self-harm which could not be firmly identified 
as such and accidental overdoses resulting from genuine errors in dosing on the part 
of patients or providers. 
Conclusion 
This study sought to describe the epidemiology of prescription opioid overdose in 
Ontario, as measured by emergency department contacts, and to explore the 
association between this outcome and the availability of specialist care. Results 
demonstrate that total contacts for opioid poisoning rose steadily across the study 
period, and that regional variation in rates is associated with the local concentration of 
specialist physicians. 
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